Despite an ASCO “sell on the news” and a severe Q2 correction some mid and small cap cancer related stocks are still up although off their highs. See commentary and news from earlier posts.
More on these and others later:
Despite an ASCO “sell on the news” and a severe Q2 correction some mid and small cap cancer related stocks are still up although off their highs. See commentary and news from earlier posts.
More on these and others later: